NSE: GLAND | BSE: 543245

Mid-range Performer

Download real time

2257.70 35.90 (1.62%)

High vol.+gain this week

NSE 21 May, 2026 11:05 AM (IST)

37,197.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Margin Growth

Gland Pharma's Q4 EBITDA margin soars 505 bps YoY, led by a richer product mix & higher utilisation See details

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

29 Jan 2026

2257.70

1.62%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Recommendation

Axis Direct

We maintain our BUY rating on the stock.

Number of FII/FPI investors decreased from 236 to 230 in Mar 2026 qtr

Gland Pharma Ltd.

29 Jan 2026

2257.70

1.62%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Number of FII/FPI investors decreased from 236 to 230 in Mar 2026 qtr

Gland Pharma Ltd.

28 Jan 2026

2257.70

1.62%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

2257.70

1.62%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma has gained 22.42% in the last 1 Week

Gland Pharma Ltd.

04 Nov 2025

2257.70

1.62%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

2257.70

1.62%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

06 Aug 2025

2257.70

1.62%

Strong margin gain boosts PAT by 50% YoY

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma has gained 23.93% in the last 3 Months

Gland Pharma Ltd.

06 Aug 2025

2257.70

1.62%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock with a target price of Rs 1,950/share.

Gland Pharma has gained 25.81% in the last 1 Month

Gland Pharma Ltd.

04 Feb 2025

2257.70

1.62%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27.

Gland Pharma has gained 22.42% in the last 1 Week

Gland Pharma Ltd.

03 Feb 2025

2257.70

1.62%

New launches and higher milestone income drive margins

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.

VOTE: Is Gland Pharma Ltd. worth buying?

215 Votes:

Buy 80.93%

Sell 9.3%

Hold 9.77%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf